UBS has adjusted its revenue forecasts for CANSINOBIO (06185), raising the 2026 estimate by 22% while lowering the 2027 projection by 9%. The bank also revised its EPS forecasts for 2025–2027 from RMB 0.24, RMB 1.16, and RMB 2.55 to RMB 0.37, RMB 1.41, and RMB 2.34, respectively. The target price was reduced from HK$66 to HK$64, with a maintained "Buy" rating.

CANSINOBIO's management reported that its MCV4 vaccine generated revenue of RMB 662 million in the first three quarters of the year, up approximately 28% year-on-year, driven by expanded age-group eligibility and continued market penetration. The vaccine began exports to Indonesia in Q3, with estimated sales reaching several million yuan this year. Additionally, the PCV13i vaccine, launched mid-year, has entered around 12 provinces, with management targeting coverage in half of China's provinces by year-end and expansion into other markets next year.